GlassScriptPhysician profile
Doran B Spencer
NPI 1053670810
$9,950.16
in general payments reported to CMS, 2019-2025
18 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $3,701 · 2021: $492 · 2022: $2,348 · 2023: $2,021 · 2024: $411 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771 · Consulting Fee: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.97 |
| Consulting Fee | $1,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $3,960.49 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,500.00 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $1,403.63 | 2022-2023 | Eylea |
| Regeneron Healthcare Solutions, INC. | $823.58 | 2021-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $413.50 | 2020-2025 | Acthar |
| Allergan, INC. | $400.00 | 2020 | |
| Genentech USA, INC. | $290.32 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $250.39 | 2022-2023 | |
| Amgen INC. | $153.85 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $136.80 | 2025 | Purified Cortrophin Gel, Iluvien |
| Abbvie INC. | $121.68 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $120.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.71 | 2019 | |
| Alimera Sciences, INC. | $99.37 | 2022 | |
| Horizon Therapeutics Plc | $81.03 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $60.59 | 2022-2025 | Xipere, Envista Envy Iol |
| Coherus Oncology, INC. | $17.39 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doran Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.